Skip to main content

Table 1 The association between ATAD2 expression and the clinicopathological variables

From: ATAD2 interacts with C/EBPβ to promote esophageal squamous cell carcinoma metastasis via TGF-β1/Smad3 signaling

Variables Cases ATAD2 Expression P
Low (%) High (%)
Gender     0.514
 Male 50 24 (48.0) 26 (52.0)  
 Female 25 14 (56.0) 11 (44.0)  
Age (years)     0.134
 < 57 39 23 (59.9) 16 (40.1)  
 ≥ 57 36 15 (41.7) 21 (58.3)  
Tumor Location     0.175
 Upper 9 4 (44.4) 5 (55.6)  
 Middle 49 22 (44.9) 27 (55.1)  
 Lower 17 12 (70.6) 5 (29.4)  
Histologic Grade     0.624
 G1 22 13 (59.1) 9 (40.9)  
 G2 33 16 (48.5) 17 (51.5)  
 G3 20 9 (45.0) 11 (55.0)  
T Status     0.054
 T1–T2 19 6 (31.6) 13 (68.4)  
 T3–T4 56 32 (57.1) 24 (42.9)  
Lymph Node Metastasis 0.002
 N0 42 28 (66.7) 14 (33.3)  
 N1,2,3 33 10 (30.3) 23 (69.7)  
TNM Stage     0.028
 I–II 36 23 (63.9) 13 (36.1)  
 III–IV 39 15 (38.5) 24 (61.5)  
Smoking     0.253
 No 25 15 (60.0) 10 (40.0)  
 Yes 50 23 (46.0) 27 (54.0)  
Alcohol     0.423
 No 44 24 (54.5) 20 (45.5)  
 Yes 31 14 (45.2) 17 (54.8)  
  1. P < 0.05 in bold